← Back to all trials
Active Not Recruiting
NCT06815354
Comprehensive Assessment of Cancer Theranostic Response
Conditions: Prostate Cancer
Sex: Male
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 25
Sponsor: AIQ Solutions
Location: Weill Medical College of Cornell New York New York
Summary
The intent of this study is to evaluate actionable outputs from TRAQinform Theranostics in a prospective, multi-center, non-interventional clinical study. The primary objective is to investigate intent-to-change treatment decisions after the addition of TRAQinform Theranostics. The exploratory objective is to investigate if treatment efficacy and treatment-related toxicity could be detected by TRAQinform Theranostics following PSMA PET/CT at week 12.
Eligibility Criteria
Inclusion Criteria:
* Age 18 years or older and willing and able to provide informed consent.
* Diagnosis of metastatic prostate cancer.
* Planned to start 177Lu-PSMA (Pluvicto).
* Ability to tolerate two 68Ga-PSMA or 18F-DCFPyL PET/CT imaging procedures. One at baseline and at 12 weeks of 177Lu-PSMA (Pluvicto) treatment.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 at screening.
Exclusion Criteria:
* Any concurrent disease, infection, or comorbid condition that interferes with the ability of the patient to participate in the trial.
Source: ClinicalTrials.gov (NCT06815354). StuddyBuddy aggregates publicly available trial information.
